MetaVia Inc. — Director's Dealing 2018

Jan 30, 2018

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Gemphire Therapeutics Inc. (GEMP)
CIK: 0001638287
Period of Report: 2018-01-29

Reporting Person: Gullans Steven R. Ph.D. (Director, Interim President & CEO)

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2018-01-29	Employee Stock Option (right to buy)	$10.44	A	60000	Acquired	2028-01-28	Common Stock (60000)	Direct

Footnotes

F1: The option vests in 12 equal consecutive monthly installments on the last day of each month, commencing on the grant date, subject to acceleration upon the appointment of a permanent President and Chief Executive Officer.